HLTRF News and Press, HLS Therapeutics Inc From 05/06/22

The following slide deck was published by HLS Therapeutics Inc. in conjunction with their 2022 Q1 earnings call. For further details see: HLS Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation

HLS Therapeutics press release (OTCPK:HLTRF): Q1 GAAP EPS of -$0.11. Revenue of $14.6M (+2.0% Y/Y) misses by $0.74M. For further details see: HLS Therapeutics GAAP EPS of -$0.11, revenue of $14.6M misses by $0.74M

HLS Therapeutics press release (OTCPK:HLTRF): Q4 GAAP EPS of -$0.13. Revenue of $15.7M (-4.8% Y/Y) misses by $0.93M. For further details see: HLS Therapeutics GAAP EPS of -$0.13, revenue of $15.7M misses by $0.93M

HLS Therapeutics Announces First Quarter Fiscal 2021 Financial Results Canada NewsWire Q1 2021 revenue of $14.3 million , Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million , up $0.4 million , $0.6 million and $1.8 million ...

HLS Therapeutics to Host Q1 2021 Financial Results Conference Call Canada NewsWire TORONTO , April 22, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021 ...

HLS Therapeutics Announces Participation in Upcoming Conferences Canada NewsWire TORONTO , April 15, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular ma...

HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults Canada NewsWire CCS dyslipidemia manag...

HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results Canada NewsWire Fourth quarter revenue of $16.5 million , Adjusted EBITDA of $8.7 million and cash from operations of $5.8 million Produced strong Vascepa® prescripti...

A new analysis supported by Amarin Corporation ([[AMRN]] +1.1%) and presented at the ongoing International Stroke Conference 2021 highlights the clinical impact of VASCEPA® (icosapent ethyl), the company announced.The presentation of REDUCE-IT® STROKE as announced by HLS Therapeutic...

HLS Therapeutics ([[HLTRF]]) announces that Amarin's ([[AMRN]] +3.0%) VASCEPA showed a 28% and 32% significant reductions in first and total strokes compared to placebo, and resulted in reductions in first and total ischemic strokes by 36%, without increasing hemorrhagic stroke, in ...